NASDAQ:OMEDOncomed Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Oncomed Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.89 0.00 (0.00 %) (As of 04/23/2019) Add Compare Share Today's Range$0.89Now: $0.89▼$0.8950-Day Range$0.89MA: $0.89▼$0.8952-Week Range$0.55Now: $0.89▼$3.35Volume1,201 shsAverage Volume768,904 shsMarket Capitalization$34.43 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. It is developing Navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors; and Phase Ib clinical trials for patients with second-line metastatic colorectal cancer, as well as in Phase Ib clinical trial in patients with platinum-resistant ovarian cancer. The company is also developing Etigilimab (Anti-TIGIT, OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia/b clinical trials for patients with advanced or metastatic solid tumors. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Oncomed Pharmaceuticals. Previous Next 2.8 Community Rank Outperform VotesOncomed Pharmaceuticals has received 319 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOncomed Pharmaceuticals has received 255 “underperform” votes. (Add your “underperform” vote.)Community SentimentOncomed Pharmaceuticals has received 55.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote “Outperform” if you believe OMED will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOncomed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOncomed Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncomed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 20.32% of the stock of Oncomed Pharmaceuticals is held by insiders.Percentage Held by Institutions45.16% of the stock of Oncomed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncomed Pharmaceuticals are expected to grow in the coming year, from ($1.00) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncomed Pharmaceuticals is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncomed Pharmaceuticals is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncomed Pharmaceuticals has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.01 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OMED Previous Symbol CUSIPN/A CIK1302573 Webwww.oncomed.com Phone650-995-8200Debt Debt-to-Equity RatioN/A Current Ratio5.04 Quick Ratio5.04Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$44.42 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book0.71Profitability EPS (Most Recent Fiscal Year)($0.16) Net Income$-8,100,000.00 Net Margins-18.24% Return on Equity-13.14% Return on Assets-7.73%Miscellaneous Employees22 Outstanding Shares38,690,000Market Cap$34.43 million Next Earnings DateN/A OptionableOptionable Receive OMED News and Ratings via Email Sign-up to receive the latest news and ratings for OMED and its competitors with MarketBeat's FREE daily newsletter. Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions How were Oncomed Pharmaceuticals' earnings last quarter? Oncomed Pharmaceuticals Inc (NASDAQ:OMED) issued its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the consensus estimate of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analysts' expectations of $7.97 million. Oncomed Pharmaceuticals had a negative net margin of 18.24% and a negative return on equity of 13.14%. View Oncomed Pharmaceuticals' earnings history. Has Oncomed Pharmaceuticals been receiving favorable news coverage? Media coverage about OMED stock has trended positive recently, InfoTrie reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a coverage optimism score of 2.4 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOncomed Pharmaceuticals. Who are some of Oncomed Pharmaceuticals' key competitors? Some companies that are related to Oncomed Pharmaceuticals include Zynerba Pharmaceuticals (ZYNE), Endonovo Therapeutics (ENDV), Evelo Biosciences (EVLO), Theratechnologies (THTX), Savara (SVRA), GlycoMimetics (GLYC), Axovant Gene Therapies (AXGT), Catabasis Pharmaceuticals (CATB), Theratechnologies (THERF), AVEO Pharmaceuticals (AVEO), SUMMIT THERAPEU/S (SMMT), OASMIA PHARMACE/ADR (OASM), InflaRx (LUMO), Recro Pharma (REPH) and Checkpoint Therapeutics (CKPT). View all competitors. What other stocks do shareholders of Oncomed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncomed Pharmaceuticals investors own include Esperion Therapeutics (ESPR), NXP Semiconductors (NXPI), GW Pharmaceuticals PLC- (GWPH), Nightstar Therapeutics (NITE), Celldex Therapeutics (CLDX), ImmunoGen (IMGN), Universal Display (OLED), Verastem (VSTM), Alnylam Pharmaceuticals (ALNY) and Clovis Oncology (CLVS). Who are Oncomed Pharmaceuticals' key executives? Oncomed Pharmaceuticals' management team includes the following people: Mr. Perry A. Karsen, Exec. Chairman (Age 64)Ms. Jill Henrich, Sr. VP of Regulatory Affairs & Quality AssuranceDr. Ann Kapoun Ph.D., Sr. VP of Translational Medicine What is Oncomed Pharmaceuticals' stock symbol? Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED." What is Oncomed Pharmaceuticals' stock price today? One share of OMED stock can currently be purchased for approximately $0.89. How big of a company is Oncomed Pharmaceuticals? Oncomed Pharmaceuticals has a market capitalization of $34.43 million and generates $44.42 million in revenue each year. The biopharmaceutical company earns $-8,100,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Oncomed Pharmaceuticals employs 22 workers across the globe. What is Oncomed Pharmaceuticals' official website? The official website for Oncomed Pharmaceuticals is www.oncomed.com. How can I contact Oncomed Pharmaceuticals? Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected] This page was last updated on 6/6/2020 by MarketBeat.com Staff
